Amgen Company Profile (NASDAQ:AMGN)

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen announced a quarterly dividend on Tuesday, March 7th. Stockholders of record on Wednesday, May 17th will be given a dividend of $1.15 per share on Thursday, June 8th. This represents a $4.60 annualized dividend and a dividend yield of 2.54%. The ex-dividend date is Monday, May 15th. View Amgen's Dividend History.

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings results on Tuesday, July, 25th. The company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The firm's revenue was up 2.1% on a year-over-year basis. During the same period last year, the business posted $2.84 EPS. View Amgen's Earnings History.

23 brokerages have issued twelve-month target prices for Amgen's stock. Their predictions range from $161.00 to $209.00. On average, they expect Amgen's share price to reach $186.53 in the next year. View Analyst Ratings for Amgen.

Here are some recent quotes from research analysts about Amgen stock:

• 1. Cann analysts commented, "Amgen reported GAAP earnings per share of $2.91, which is 3.2% higher than our estimate of $2.83. Earnings exceeded our expectations due to higher than estimated product sales and a lower than estimated tax rate. Higher than estimated product sales were primarily driven by higher sales of Aranesp, Kyprolis, Blincyto, and Sensipar. Nearly all of Amgen’s products exceeded our estimates for International sales. Total product sales of $5.57 billion exceeded our estimated $5.47 billion by 1.8% and exceeded consensus product sales by 2.7%." (7/26/2017)
• 2. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
• 3. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)
• 4. According to Zacks Investment Research, "Amgen growth products – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are performing well. Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. Amgen has a positive record of earnings surprises in recent quarters. Amgen’s shares surpassed that of Biomed-Genetics industry in 2016. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. Biosimilars are starting to have a negative impact on key products like Neupogen and Neulasta in the EU. Moreover, minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017. Estimates have also declined lately ahead of the company’s Q4 earnings release." (1/3/2017)

Some companies that are related to Amgen include Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), bluebird bio (BLUE), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), BeiGene (BGNE), GW Pharmaceuticals PLC (GWPH), Agios Pharmaceuticals (AGIO) and China Biologic Products (CBPO).

Amgen's management team includes the folowing people:

• Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
• David W. Meline, Executive Vice President, Chief Financial Officer
• Sean E. Harper, Executive Vice President - Research and Development
• Anthony C. Hooper, Executive Vice President - Global Commercial Operations
• Brian M. McNamee, Executive Vice President - Full Potential Initiatives
• Esteban Santos, Executive Vice President, Operations
• Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
• Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
• Lori A. Johnston, Senior Vice President
• David A. Piacquad, Senior Vice President - Business Development

Amgen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.37%), APG Asset Management N.V. (0.22%), NN Investment Partners Holdings N.V. (0.12%), US Bancorp DE (0.10%), AMF Pensionsforsakring AB (0.09%) and Chevy Chase Trust Holdings Inc. (0.09%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Fred Hassan, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Amgen's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Assenagon Asset Management S.A., Bank of Montreal Can, NN Investment Partners Holdings N.V., ING Groep NV, Boston Advisors LLC, Douglas Lane & Associates LLC and Russell Investments Group Ltd.. Company insiders that have sold Amgen stock in the last year include Annette Louise Such and Cynthia M Patton. View Insider Buying and Selling for Amgen.

Amgen's stock was purchased by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Mn Services Vermogensbeheer B.V., Grimes & Company Inc., National Pension Service, Manning & Napier Advisors LLC, Personal Capital Advisors Corp, Swedbank and Aperio Group LLC. View Insider Buying and Selling for Amgen.

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Amgen stock can currently be purchased for approximately $180.89.